Journal
SCHIZOPHRENIA RESEARCH
Volume 125, Issue 1, Pages 88-92Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.schres.2010.09.025
Keywords
MK-801; PAOPA; Social interaction; Non-competitive NMDA antagonist; Dopamine D-2 receptor
Categories
Funding
- National Institutes of Health Research [2R01-NS020036-20]
- NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS020036] Funding Source: NIH RePORTER
Ask authors/readers for more resources
The aim of this study was to investigate whether a potent analogue of the endogenous brain peptide L-prolyl-L-leucyl-glycinamide (PLO), (3(R)-[(2(S)-pyrrolidinylcarbonyl)amino]-2-oxo-1-pyrrolidineacetamide (PAOPA), can prevent the induction of social withdrawal caused by sub-chronic treatment with the non-competitive NMDA (N-methyl-L-aspartate) receptor antagonist, MK-801. Results indicate that MK-801 (0.5 mg/kg) significantly decreased social interaction following sub-chronic treatment (7 days). Treatment with PAOPA (1 mg/kg) blocked the effects of MK-801, and increased the amount of time spent in social interaction in comparison to control animals. These results provide evidence for the development of peptidomimetic compounds for the treatment of social withdrawal and related negative symptoms associated with schizophrenia. (C) 2010 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available